315 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Kelly
    Kelly
  4. Gerecitano
    Gerecitano
  5. O'Reilly
    O'Reilly
  6. Slovin
    Slovin
  7. Smart-Curley
    Smart-Curley
  8. Morris
    Morris
  9. Schwartz
    Schwartz
  10. Zelenetz
    Zelenetz

Groups

  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)
  7. Biostatistics Service (45)
  8. Survivorship Research (45)
  9. Radiology, Department of (42)
  10. Nursing (41)
  1. "hyperglycemia"
Formats
  1. Journal Article (294)
  2. Review (17)
  3. Guidelines (2)
  4. Correspondence (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)

More Groups

People
  1. Robert Motzer (28)
  2. Howard Scher (15)
  3. William Kelly (14)
  4. Eileen O'Reilly (11)
  5. John Gerecitano (11)
  6. Susan Slovin (11)

More People

Years
  1. 2025 (8)
  2. 2024 (20)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (9)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (27)
  2. Clinical Cancer Research (20)
  3. Cancer (14)
  4. Lancet Oncology (14)
  5. Annals of Oncology (12)
  6. Investigational New Drugs (12)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Springer (32)
  3. American Society of Clinical Oncology (28)
  4. Elsevier Science, Inc. (23)
  5. Oxford University Press (23)
  6. American Association for Cancer Research (21)

More Publishers

Results (315)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alliance A061202: Ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
    Journal Article

    Voorhees, P.; Suman, V.; Efebera, Y.; Raje, N.; Tuchman, S.; Rodriguez, C.; Laubach, J.; Bova-Solem, M.; Carlisle, D.; Usmani, S.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
    Journal Article

    Brown, J.; Miller, A.; Holman, L. L.; Backes, F.; Nagel, C.; Bender, D.; Miller, D. S.; Powell, M. A.; Westin, S. N.; Bonebrake, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
    Journal Article

    Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K. L.; Krivorotko, P.; Loibl, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): Current progress and latest advances
    Review

    Schaff, L.; Nayak, L.; Grommes, C.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
    Journal Article

    Ahluwalia, M. S.; Peereboom, D. M.; Ozair, A.; Khosla, A. A.; Ozair, A.; Rudek, M.; Ye, X.; Holdhoff, M.; Grossman, S. A.; Ye, X.; more...
    Cell Reports Medicine (2024)

    Fulltext@MSK | Save
  • Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): A randomised, open-label, phase 3 trial from the Children's Oncology Group
    Journal Article

    Gupta, A. A.; Xue, W.; Harrison, D. J.; Hawkins, D. S.; Dasgupta, R.; Wolden, S.; Shulkin, B.; Qumseya, A.; Routh, J. C.; MacDonald, T.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer
    Review

    Pearson, A. D. J.; DuBois, S. G.; Macy, M. E.; de Rojas, T.; Donoghue, M.; Weiner, S.; Knoderer, H.; Bernardi, R.; Buenger, V.; Canaud, G.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Clinical pharmacology of the antibody–drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors
    Review

    Tang, M.; Garg, A.; Bonate, P. L.; Rosenberg, J. E.; Matsangou, M.; Kadokura, T.; Yamada, A.; Choules, M.; Pavese, J.; Nagata, M.; more...
    Clinical Pharmacokinetics (2024)

    Fulltext@MSK | Save
  • Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
    Review

    Brower, B.; McCoy, A.; Ahmad, H.; Eitman, C.; Bowman, I. A.; Rembisz, J.; Milowsky, M. I.
    Frontiers in Oncology (2024)

    Fulltext@MSK | Save
  • A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer
    Journal Article

    Rodón, J.; Demanse, D.; Rugo, H. S.; Burris, H. A.; Simó, R.; Farooki, A.; Wellons, M. F.; André, F.; Hu, H.; Vuina, D.; more...
    Breast Cancer Research (2024)

    Fulltext@MSK | Save